Experimental cancer drug GEN1047 tested in humans – study halted early
NCT ID NCT05180474
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug called GEN1047 in people with advanced solid tumors (breast, endometrial, ovarian, or lung cancer) who had no other treatment options. The goal was to check safety, side effects, and how the body processes the drug. The study was terminated early, but the data may still help understand the drug's potential.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER, BREAST NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Antwerp University Hospital
Edegem, 2650, Belgium
-
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
CHU Poitiers - Hôpital la Milétrie
Poitiers, France
-
CHU de Besancon
Besançon, 25030, France
-
Case Western Reserve University
Cleveland, Ohio, 44106, United States
-
Centre Léon Bérard
Lyon, 69008, France
-
Centro Oncologico Clara Campal
Madrid, 28050, Spain
-
Clinica Universidad de Navarra
Pamplona, 31008, Spain
-
Erasmus Medisch Centrum
Rotterdam, 3015CE, Netherlands
-
Fondazione IRCCS San Gerardo dei Tintori
Monza, 20900, Italy
-
Hospital Clinic de Barcelona
Barcelona, Spain
-
Hospital Clinico Universitario de Valencia
Valencia, Spain
-
Hospital Ruber Internacional
Madrid, 28034, Spain
-
Hospital Universitari Vall d'Hebron
Barcelona, 8035, Spain
-
Hospital Universitary Fundacion Jimenez Diaz
Madrid, 2815, Spain
-
Hôpital Cochin
Paris, France
-
IEO Istituto Europeo di Oncologia
Milan, 435, Italy
-
Institut Bergonié
Bordeaux, France
-
Institut Claudius Regaud
Toulouse, France
-
Institut Curie
Paris, 75248, France
-
Institut Gustave Roussy
Villejuif, 75005, France
-
Institut du Cancer de Montpellier
Montpellier, 34298, France
-
MD Anderson Cancer Center
Madrid, 28033, Spain
-
Med-Polonia Sp. z o.o
Poznan, Poland
-
NEXT Oncology Madrid
Madrid, Spain
-
Radboudumc
Nijmegen, 6525GA, Netherlands
-
Rigshospitalet (Copenhagen University Hospital)
Copenhagen, 2100, Denmark
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
St Bartholomews Hospital
London, EC1A7BE, United Kingdom
-
The Christie Hospital
Manchester, M20 4BX, United Kingdom
-
UCLA Department of Medicine Hematology Oncology
Los Angeles, California, 90024, United States
-
Universitair Ziekenhuis Leuven
Leuven, 3000, Belgium
-
University College London Hospital
London, NW1 2BU, United Kingdom
-
University Medical Center Groningen
Groningen, 9713GZ, Netherlands
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Yale University - Yale Cancer Center
New Haven, Connecticut, 06520-8028, United States